Evidence map›Paper›PMID 32166656›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2020

Diffusible and volatile organic compounds produced by avocado rhizobacteria exhibit antifungal effects against Fusarium kuroshium.

Edgar Guevara-Avendaño, Karla R Bravo-Castillo, Juan L Monribot-Villanueva, Ana L Kiel-Martínez, Mónica Ramírez-Vázquez, José A Guerrero-Analco, Frédérique Reverchon

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Edgar Guevara-AvendañoRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México.ORCID https://orcid.org/0000-0002-0432-4833
Karla R Bravo-CastilloRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México.
Juan L Monribot-VillanuevaRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México.
Ana L Kiel-MartínezRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México.
Mónica Ramírez-VázquezRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México.ORCID https://orcid.org/0000-0003-1801-0138
José A Guerrero-AnalcoRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Carretera antigua a Coatepec 351, Col. El Haya, 91070, Xalapa, Veracruz, México. joseantonio.guerrero@inecol.mx.ORCID https://orcid.org/0000-0003-0998-757X
Frédérique ReverchonRed de Estudios Moleculares Avanzados, Instituto de Ecología, A.C., Calle Prol. Lázaro Cárdenas 253, Col. Centro, 61600, Pátzcuaro, Michoacán, México. frederique.reverchon@inecol.mx.ORCID https://orcid.org/0000-0002-5864-7494
Instituto de Ecología · MXTechnological University of the Mixteca · MXUniversidad Veracruzana · MX

Funding

agreement SENASICA-INECOL 2016(Fondo Nacional de Desarrollo Científico y Tecnológico or FORDECyT 292399
6 · The paper itself

Abstract

Rhizobacteria emit bioactive metabolites with antifungal properties that could be used for biocontrol of fungal diseases. In this study, we evaluated the potential of diffusible and volatile organic compounds (VOCs) emitted by avocado rhizobacteria to inhibit the growth of Fusarium kuroshium, one of the causal agents of Fusarium dieback (FD) in avocado. Three bacterial isolates (INECOL-6004, INECOL-6005, and INECOL-6006), belonging to the Bacillus genus, were selected based on their capacity to inhibit several avocado fungal pathogens, and tested in antagonism assays against F. kuroshium. The three bacterial isolates significantly inhibited F. kuroshium mycelial growth by up to 48%. The composition of bacterial diffusible compounds was characterized by the analysis of EtOAc and n-BuOH extracts by using ultra-performance liquid chromatography (UPLC) coupled to high-resolution mass spectrometry (HRMS). The three bacterial isolates produced cyclo-lipopeptides belonging to the iturin, fengycin, and surfactin families. The antifungal activity of n-BuOH extracts was larger than that of EtOAc extracts, probably due to the greater relative abundance of fengycin in the former than in the latter. In addition, isolates INECOL-6004 and INECOL-6006 significantly inhibited F. kuroshium mycelial growth through VOC emission by up to 69.88%. The analysis of their VOC profiles by solid phase micro-extraction (SPME) coupled to gas chromatography and mass spectrometry (GC-MS) revealed the presence of ketones and pyrazine compounds, particularly of 2-nonanone, which was not detected in the VOC profile of isolate INECOL-6005. These results emphasize the need to further investigate the antifungal activity of each bioactive compound for the development of new formulations against fungal phytopathogens.

Indexed as

AntibiosisAntifungal AgentsBacillusFusariumLipopeptidesMyceliumPerseaPlant DiseasesSoil MicrobiologyVolatile Organic CompoundsAntifungal AgentsLipopeptidesVolatile Organic CompoundsBacillusBacterial lipopeptidesBiological controlFusarium diebackPersea americana

Identifiers

PMID32166656
PMCPMC7455650
OpenAlexW3011422517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.